|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1445 New York Avenue, NW, #800 |
Address2 |
|
City | WASHINGTON |
State | DC |
Zip Code | 20005 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 1331-12
|
||||||||
|
6. House ID# 303290000
|
TYPE OF REPORT | 8. Year | 2014 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Shawn Friesen |
Date | 10/20/2014 4:05:01 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Advocate for improved access to specialty drugs for patients with chronic conditions (H.R. 460, Patients' Access to Treatments Act of 2013).
Advocate for truth in advertising for health care providers (H.R. 1427, Truth in Healthcare Marketing Act of 2013).
Lobby Members of Congress to join the Congressional Skin Cancer Caucus.
Lobby Congress to protect and preserve the in-office use of compounded pharmaceuticals without a patient prescription (H.R. 3204, Drug Quality and Security Act/Public Law No: 113-54).
Lobby Congress on legislation to remove non-discrimination requirements relating to health care providers. (H.R. 2817, Protect Patient Access to Quality Health Professionals Act of 2013).
Advocate for legislation that would allow for Flexible Spending Accounts (FSAs) to be used to cover over-the-counter (OTC) drugs (S. 1647, H.R. 2835, Restoring Access to Medication Act).
Lobby Congress on legislation to create a transparent and predictable review process for sunscreen ingredients (S. 2141/H.R. 4250 Sunscreen Innovation Act).
Lobby Congress on issues related to telemedicine.
Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks.
Advocate on on use and availability of health care data.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Niva |
Haynes |
|
|
|
Katie |
Jones |
|
|
|
Christine |
O'Connor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, and Food and Drug Administration (FY 15 Labor/HHS/Education Appropriations and FY 15 Agriculture Appropriations program request).
Support legislation to adjust discretionary spending caps for biomedical research (S. 2658/H.R. 5580, Accelerating Biomedical Research Act).
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Niva |
Haynes |
|
|
|
Katie |
Jones |
|
|
|
Christine |
O'Connor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Support legislation to eliminate the Independent Payment Advisory Board (S.351, H.R. 351, Protecting Seniors' Access to Medicare Act of 2013).
Support legislation to increase residency slots for Graduate Medical Education (H.R. 1201, Training Tomorrow's Doctors Today Act).
Lobby in support of legislation to enact a permanent repeal to the Medicare sustainable growth rate (S.2000/H.R. 4015; SGR Repeal and Medicare Provider Payment Modernization Act of 2014 ).
Lobby in support of a cap on the amount CMS can decrease payment to physician services in a given year. (related provision included in S.2000/H.R. 4015; SGR Repeal and Medicare Provider Payment Modernization Act of 2014 and H.R. 4302, Protecting Access to Medicare Act).
Lobby Congress in opposition to proposed legislation to repeal in-office ancillary and physician services for anatomic pathology services (H.R. 2914, Promoting Integrity in Medicare Act of 2013, FY 15 President's Budget).
Lobby Congress on impact of Health Information Technology.
Lobby Congress to stop sequestration cuts to Medicare physician payments (Bipartisan Budget Act of 2013).
Lobby in support of increased transparency and adequate response time from CMS when setting values for misvalued codes.
Oppose legislation allowing non-physician providers direct access to Medicare patients without a referral (H.R. 5304, Audiology Patient Choice Act of 2014).
Advocate on issues related to waste, fraud and abuse in Medicare.
Advocate regarding use and release of Medicare data regarding services provide by physicians.
Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage networks (S. 2552/H.R. 4998, Medicare Advantage Participant Bill of Rights Act of 2014).
Lobby Congress on issues related to telemedicine (H.R. 5380, the Medicare Telehealth Parity Act).
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Niva |
Haynes |
|
|
|
Katie |
Jones |
|
|
|
Christine |
O'Connor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TOR
16. Specific lobbying issues
Support legislation to enact medical liability reform (H.R. 1473, the Standard of Care Protection Act).
Support inclusion of standard of care provisions similar to H.R. 1473 in S.2000/H.R. 4015.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Niva |
Haynes |
|
|
|
Katie |
Jones |
|
|
|
Christine |
O'Connor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |